Clinical and research applications of simultaneous positron emission tomography and MRI.
Evaluation of the molecular processes responsible for disease pathogenesis and progression represents the new frontier of clinical radiology. Multimodality imaging lies at the cutting edge, combining the power of MRI for tissue characterization, microstructural appraisal and functional assessment together with new positron emission tomography (PET) tracers designed to target specific metabolic processes. The recent commercial availability of an integrated clinical whole-body PET-MRI provides a hybrid platform for exploring and exploiting the synergies of multimodal imaging. First experiences on the clinical and research application of hybrid PET-MRI are emerging. This article reviews the rapidly evolving field and speculates on the potential future direction.
Institute of Nuclear Medicine, University College London, London, UK.
F
F
Fraioli
S
S
Punwani
D000368:Aged; D001927:Brain Diseases / Q000175:diagnosis*; D002318:Cardiovascular Diseases / Q000175:diagnosis; D006801:Humans; D007249:Inflammation / Q000175:diagnosis; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging / Q000379:methods; D009369:Neoplasms / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D051598:Whole Body Imaging / Q000379:methods*